Prognostic impact of histological subtyping in triple-negative breast cancer

被引:0
|
作者
Grosse, Claudia [1 ]
Noack, Petar [1 ]
Grosse, Alexandra [2 ]
Preuss, Caroline Ines [3 ]
Schwarz, Heike Kathleen [4 ]
Gitter, Thomas [5 ]
Schrenk, Peter [6 ]
Frauchiger-Heuer, Heike [7 ,8 ]
Papassotiropoulos, Barbel [9 ]
Tausch, Christoph [9 ]
Maccio, Umberto [10 ]
Moch, Holger [10 ]
Langer, Rupert [1 ]
Varga, Zsuzsanna [8 ,10 ]
机构
[1] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Pathol & Mol Pathol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[2] Pathol Inst Enge, Hardturmstr 133, CH-8005 Zurich, Switzerland
[3] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Gynecol Obstet & Gynecol Endocrinol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[4] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Hematol & Oncol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[5] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Cent Radiol Inst, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[6] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Gen & Visceral Surg, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[7] Univ Hosp Zurich, Clin Gynecol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland
[8] Univ Hosp Zurich, Comprehens Breast Canc Ctr, Zurich, Switzerland
[9] Breast Ctr Seefeld, Seefeldstr 214, CH-8008 Zurich, Switzerland
[10] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland
关键词
Breast cancer; Triple-negative phenotype; special histological types; Prognostic stratification; Therapy response; CLINICOPATHOLOGICAL FEATURES; METAPLASTIC CARCINOMA; SURVIVAL OUTCOMES; HETEROGENEITY; DISEASE; SUBSET;
D O I
10.1016/j.humpath.2024.105640
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The impact of special histological types (ST) in triple-negative breast cancer (TNBC) and its association with overall outcome has gained increasing relevance as survival has been linked to specific histological TNBC subtypes. We evaluated the clinicopathological and survival data of 598 patients with 613 TNBCs, including 464 TNBCs of no special type (NST) and 149 TNBCs ST (low-grade, n = 12, 8.1%; high-grade, n = 112, 75.2%; apocrine and androgen receptor-positive [APO AR], n = 25, 16.8%). Patients with low-grade TNBC ST and TNBC ST APO AR were significantly older (P G 0.001) and had a lower Ki67 index (P G 0.001) than those with TNBC NST. Patients with high-grade TNBC ST were significantly older (P = 0.006) and had poorer pathological responses to neoadjuvant chemotherapy (NAC) (P G 0.001) than those with TNBC NST. Significant survival differences were observed between low-grade TNBC ST, TNBC ST APO AR, high-grade TNBC ST, and TNBC NST in the entire study group (DFS, P = 0.002; DDFS, P = 0.001) and in the non-NAC subgroup (OS, P = 0.034; DFS, P = 0.001; DDFS, P G 0.001). Patients with low-grade TNBC ST had the best survival outcomes. Patients with highgrade TNBC ST showed significantly worse outcomes than those with TNBC NST (entire study group: OS, P = 0.049; DFS, P G 0.001; DDFS, P = 0.001; non-NAC subgroup: OS, P = 0.014; DFS, P G 0.001; DDFS, P G 0.001). We conclude that prognostic stratification of TNBC ST is ultimately important for optimizing the therapeutic management of patients with these rare tumor entities.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Endocan as a prognostic biomarker of triple-negative breast cancer
    Sagara, Atsunobu
    Igarashi, Katsuhide
    Otsuka, Maky
    Kodama, Akihiro
    Yamashita, Mutsumi
    Sugiura, Rei
    Karasawa, Takeshi
    Arakawa, Kazuhiko
    Narita, Michiko
    Kuzumaki, Naoko
    Narita, Minoru
    Kato, Yoshinori
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (02) : 269 - 278
  • [22] Prognostic values of EDNRB in triple-negative breast cancer
    Liu, Shaoqing
    Zhang, Jingyang
    Zhu, Jiujun
    Jiao, Dechuang
    Liu, Zhenzhen
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [23] Prognostic significance of triple-negative phenotype in breast cancer
    Choi, M. Y.
    Lee, K. E.
    Chang, H. J.
    Sung, S. H.
    Moon, B. I.
    Choi, H. Y.
    Suh, H. S.
    Nam, E. M.
    Mun, Y. C.
    Seong, C. M.
    Lee, S. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Endocan as a prognostic biomarker of triple-negative breast cancer
    Atsunobu Sagara
    Katsuhide Igarashi
    Maky Otsuka
    Akihiro Kodama
    Mutsumi Yamashita
    Rei Sugiura
    Takeshi Karasawa
    Kazuhiko Arakawa
    Michiko Narita
    Naoko Kuzumaki
    Minoru Narita
    Yoshinori Kato
    Breast Cancer Research and Treatment, 2017, 161 : 269 - 278
  • [25] Prognostic significance of triple-negative phenotype in breast cancer
    Lee, K. E.
    Choi, M. Y.
    Chang, H. J.
    Sung, S. H.
    Moon, B. I.
    Choi, H. Y.
    Nam, E. M.
    Mun, Y. C.
    Seong, C. M.
    Lee, S. N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 188 - 188
  • [26] Clinicopathologic and Prognostic Characteristics of Triple-Negative Breast Cancer
    Tian, Xing-song
    Cong, Ming-hua
    Zhou, Wen-hong
    Zhu, Jian
    Chen, Yue-zhi
    Liu, Qi
    ONKOLOGIE, 2008, 31 (11): : 610 - 614
  • [27] Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
    Cserni, Gabor
    Quinn, Cecily M.
    Foschini, Maria Pia
    Bianchi, Simonetta
    Callagy, Grace
    Chmielik, Ewa
    Decker, Thomas
    Fend, Falko
    Kovacs, Aniko
    van Diest, Paul J.
    Ellis, Ian O.
    Rakha, Emad
    Tot, Tibor
    CANCERS, 2021, 13 (22)
  • [28] The Epidemiology, Clinico-Pathologic and Prognostic Characteristics of Triple-Negative Breast Cancer Compared with Non Triple-Negative Breast Cancer
    Kwong, A.
    Wong, K.
    Wong, C. H. N.
    Leung, C.
    CANCER RESEARCH, 2009, 69 (24) : 669S - 669S
  • [29] Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer
    Choi, Y. S.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S709 - S710
  • [30] Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
    Tong, Ling
    Yu, Xiangling
    Wang, Shan
    Chen, Ling
    Wu, Yibo
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 647 - 658